News
Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.
Press Releases
Nov 09, 2023
Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol NDA-enabling Phase 3 studies in 2024 underway Itruvone (PH10) staged for potential Phase 2B
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that
Positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by SAD expert, Dr. Michael Liebowitz , at CNS Summit 2023 Positive results from PH80 Phase 2A study in women diagnosed with vasomotor symptoms (hot flashes) due to menopause
Nov 06, 2023
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it